購物車 
-
雷地尼唑
- names：
Ridinilazole
- CAS號(hào)：
308362-25-6
MDL Number： MFCD28963972 - MF(分子式)： C24H16N6 MW(分子量)： 388.42
- EINECS: Reaxys Number:
- Pubchem ID:16659285 Brand:BIOFOUNT
雷地尼唑(Ridinilazole,SMT19969,308362-25-6)利迪尼唑是一種不可吸收的小分子抗生素，可口服用于治療艱難梭菌感染（CDI），與標(biāo)準(zhǔn)的萬古霉素相比，在持續(xù)臨床反應(yīng)（SCR）率方面顯示出統(tǒng)計(jì)學(xué)優(yōu)勢。
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000108-1mg | 1mg | 99.51% | ￥ 975.00 | ￥ 975.00 | 2-3天 | ￥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購物車 立即購買
| 中文別名 | 雷地尼唑(308362-25-6);利地利唑;利迪尼唑; SMT-19969；SMT 19969；SMT19969；Ridinilazole2,2'-二（吡啶-4-基）-1H，1'H-5,5'-聯(lián)（苯并咪唑);（2,2'雙（4-吡啶基）3H，3'H 5,5'聯(lián)苯并咪唑; |
| 英文別名 | Ridinilazole(308362-25-6);SMT-19969; SMT 19969; SMT19969; Ridinilazole2,2'-di(pyridin-4-yl)-1H,1'H-5,5'-bi(benzimidazole);(2,2' bis(4-pyridyl) 3H,3'H 5,5' bibenzimidazole; |
| CAS號(hào) | 308362-25-6 |
| Inchi | InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30) |
| InchiKey | UHQFBTAJFNVZIV-UHFFFAOYSA-N |
| 分子式 Formula | C24H16N6 |
| 分子量 Molecular Weight | 388.42 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 60 mg/mL(154.47 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 固體粉末,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C ,3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
雷地尼唑(Ridinilazole,SMT19969,308362-25-6)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:雷地尼唑試劑,雷地尼唑雜質(zhì),雷地尼唑合成,雷地尼唑中間體,雷地尼唑密度,雷地尼唑閃點(diǎn),雷地尼唑熔點(diǎn),雷地尼唑結(jié)構(gòu)式,雷地尼唑溶解度,雷地尼唑購買,
| 產(chǎn)品說明 | 雷地尼唑(Ridinilazole,SMT19969,308362-25-6)是一種不可吸收的小分子抗生素,可用于治療艱難梭菌感染(CDI) |
| Introduction | 雷地尼唑(Ridinilazole,SMT19969,308362-25-6)is a novelantibacterialwith MICs range of 0.06.25μg/mL (MIC90=8μg/mL) againstC.difficile. |
| Application1 | 雷地尼唑(Ridinilazole,SMT19969,308362-25-6)與標(biāo)準(zhǔn)的萬古霉素相比，在持續(xù)臨床反應(yīng)（SCR）率方面顯示出統(tǒng)計(jì)學(xué)優(yōu)勢。是一種有效的新型的抗菌劑，作用于C.difficile，MIC 范圍是 0.06-0.25μg/mL (MIC90=8μg/mL) |
| Application2 | |
| Application3 |
雷地尼唑(Ridinilazole,SMT19969,308362-25-6)藥理學(xué)：
1、利迪尼唑正在臨床試驗(yàn)NCT02092935中進(jìn)行研究（將SMT19969與萬古霉素比較用于治療艱難梭菌相關(guān)性腹瀉（CDAD））。
2、利迪尼唑是一種不可吸收的小分子抗生素，可口服用于治療艱難梭菌感染（CDI），與標(biāo)準(zhǔn)的萬古霉素相比，在持續(xù)臨床反應(yīng)（SCR）率方面顯示出統(tǒng)計(jì)學(xué)優(yōu)勢。
1、利迪尼唑正在臨床試驗(yàn)NCT02092935中進(jìn)行研究（將SMT19969與萬古霉素比較用于治療艱難梭菌相關(guān)性腹瀉（CDAD））。
2、利迪尼唑是一種不可吸收的小分子抗生素，可口服用于治療艱難梭菌感染（CDI），與標(biāo)準(zhǔn)的萬古霉素相比，在持續(xù)臨床反應(yīng)（SCR）率方面顯示出統(tǒng)計(jì)學(xué)優(yōu)勢。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食入，做好安全防護(hù) |
| Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43. |
| Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin PMID 29718329; The Journal of antimicrobial chemoth |
| Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection PMID 26895772; The Journal of antimicrobial chemotherap |
| SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI PMID 25652749; The Journal of antimicrobial chemotherapy 2015; |
| Therapy of Clostridium difficile infection: perspectives on a changing paradigm PMID 24053182; Expert opinion on pharmacotherapy 2013 Dec; 14(17):2375-86 (Review Article) Name matches: fidaxomicin smt |
雷地尼唑(Ridinilazole,SMT19969,308362-25-6)參考文獻(xiàn)：
1.Exploring ways to improve CDI outcomes.
Galpérine T;Guery B;French Group of Fecal Microbiota Transplantation (GFTF) Med Mal Infect. 2018 Feb;48(1):10-17. doi: 10.1016/j.medmal.2017.10.009. Epub 2018 Jan 12.
Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus recognized as an evolving international health problem. Metronidazole and vancomycin were - until recently - the only drugs available to treat C. difficile infection (CDI). Better knowledge of the pathophysiology and the development of new drugs completely modified the management of initial episodes and recurrences of CDI. Fidaxomicin significantly reduced recurrences compared with vancomycin. New drugs are also currently evaluated (cadazolid, surotomycin, ridinilazole, rifaximin). Gut microbiota homeostasis was clearly shown to be a key determinant in recurrences as demonstrated by the development of gut microbiota transplantation and alternative microbiota substitution. Passive immunotherapy and vaccinal approaches are also currently being evaluated. In conclusion, CDI treatment has evolved with the development of new therapeutic pathways which now need to be implemented in international guidelines.
2.Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
Snydman DR;McDermott LA;Thorpe CM;Chang J;Wick J;Walk ST;Vickers RJ J Antimicrob Chemother. 2018 Aug 1;73(8):2078-2084. doi: 10.1093/jac/dky135.
Objectives: ;We evaluated the antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from participants in a Phase 2 study of ridinilazole, a novel targeted-spectrum agent for treatment of C. difficile infection.;Methods: ;Participants received ridinilazole (200 mg twice daily) or vancomycin (125 mg four times daily) for 10 days (ClinicalTrials.gov: ;NCT02092935;). The MICs of ridinilazole and comparators for C. difficile isolates from stool samples were determined by agar dilution. Toxin gene profiling was performed by multiplex PCR and ribotype identification by capillary electrophoresis.;Results: ;Eighty-nine isolates were recovered from 88/100 participants (one participant had two strains at baseline). The median colony count (cfu/g stool) was 1.9?×?104 (range: 2.5?×?102-7.0?×?106). Twelve participants (three received ridinilazole and nine received vancomycin) experienced recurrence, confirmed by immunoassays for free toxin in stool samples. The ribotype of eight out of nine isolates obtained at recurrence matched those of the initial isolates. All isolates, including those obtained at recurrence, were susceptible to ridinilazole within the expected range [median (range) MIC: 0.
3.New and emerging therapies for Clostridium difficile infection.
Martin J;Wilcox M Curr Opin Infect Dis. 2016 Dec;29(6):546-554.
PURPOSE OF REVIEW: ;Clostridium difficile infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions. Multiple new approaches to the prevention and treatment of C. difficile infection (CDI) are undergoing clinical trials.;RECENT FINDINGS: ;Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase III studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics. Antibiotics under development include cadazolid and ridinilazole, whereas surotomycin has had disappointing phase III results. Multiple live biotherapeutics are being developed, including freeze thawed and encapsulated versions of faecal microbiota transplantation to improve the practicality of treating patients with recurrent CDI. Alternatives to faecal microbiota transplantation, that aim to improve safety, including a microbial suspension, RBX2660, and a complex spore formulation, SER-109, have progressed to phase II studies. A nontoxigenic C. difficile strain has also shown promise to prevent recurrent CDI. In addition, three C. difficile vaccines have progressed to phase II/III clinical trials.
1.Exploring ways to improve CDI outcomes.
Galpérine T;Guery B;French Group of Fecal Microbiota Transplantation (GFTF) Med Mal Infect. 2018 Feb;48(1):10-17. doi: 10.1016/j.medmal.2017.10.009. Epub 2018 Jan 12.
Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus recognized as an evolving international health problem. Metronidazole and vancomycin were - until recently - the only drugs available to treat C. difficile infection (CDI). Better knowledge of the pathophysiology and the development of new drugs completely modified the management of initial episodes and recurrences of CDI. Fidaxomicin significantly reduced recurrences compared with vancomycin. New drugs are also currently evaluated (cadazolid, surotomycin, ridinilazole, rifaximin). Gut microbiota homeostasis was clearly shown to be a key determinant in recurrences as demonstrated by the development of gut microbiota transplantation and alternative microbiota substitution. Passive immunotherapy and vaccinal approaches are also currently being evaluated. In conclusion, CDI treatment has evolved with the development of new therapeutic pathways which now need to be implemented in international guidelines.
2.Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
Snydman DR;McDermott LA;Thorpe CM;Chang J;Wick J;Walk ST;Vickers RJ J Antimicrob Chemother. 2018 Aug 1;73(8):2078-2084. doi: 10.1093/jac/dky135.
Objectives: ;We evaluated the antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from participants in a Phase 2 study of ridinilazole, a novel targeted-spectrum agent for treatment of C. difficile infection.;Methods: ;Participants received ridinilazole (200 mg twice daily) or vancomycin (125 mg four times daily) for 10 days (ClinicalTrials.gov: ;NCT02092935;). The MICs of ridinilazole and comparators for C. difficile isolates from stool samples were determined by agar dilution. Toxin gene profiling was performed by multiplex PCR and ribotype identification by capillary electrophoresis.;Results: ;Eighty-nine isolates were recovered from 88/100 participants (one participant had two strains at baseline). The median colony count (cfu/g stool) was 1.9?×?104 (range: 2.5?×?102-7.0?×?106). Twelve participants (three received ridinilazole and nine received vancomycin) experienced recurrence, confirmed by immunoassays for free toxin in stool samples. The ribotype of eight out of nine isolates obtained at recurrence matched those of the initial isolates. All isolates, including those obtained at recurrence, were susceptible to ridinilazole within the expected range [median (range) MIC: 0.
3.New and emerging therapies for Clostridium difficile infection.
Martin J;Wilcox M Curr Opin Infect Dis. 2016 Dec;29(6):546-554.
PURPOSE OF REVIEW: ;Clostridium difficile infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions. Multiple new approaches to the prevention and treatment of C. difficile infection (CDI) are undergoing clinical trials.;RECENT FINDINGS: ;Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase III studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics. Antibiotics under development include cadazolid and ridinilazole, whereas surotomycin has had disappointing phase III results. Multiple live biotherapeutics are being developed, including freeze thawed and encapsulated versions of faecal microbiota transplantation to improve the practicality of treating patients with recurrent CDI. Alternatives to faecal microbiota transplantation, that aim to improve safety, including a microbial suspension, RBX2660, and a complex spore formulation, SER-109, have progressed to phase II studies. A nontoxigenic C. difficile strain has also shown promise to prevent recurrent CDI. In addition, three C. difficile vaccines have progressed to phase II/III clinical trials.
對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實(shí)驗(yàn)室中是通用的，可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51
